In This Section

Home / Blurb / Discussion List

NCCN Updates Colorectal Cancer Guidelines to Include Braftovi and Mektovi

Mar 26, 2019, 12:13 PM
On March 18, Array BioPharma Inc. announced that the National Comprehensive Cancer Network has updated their Clinical Practice Guidelines to include Braftovi (encorafenib) in combination with Mektovi (binimetinib) and an anti-EGFR antibody as a Category 2a treatment for patients with BRAF-mutant metastatic colorectal cancer (mCRC) after failure of one or two prior lines of therapy for metastatic disease.

Read the Array press release here.

Posted 3/26/2019

Leave a comment